The acute care syndromic testing market size has grown rapidly in recent years. It will grow from $4.59 billion in 2025 to $5.17 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to emergency infection diagnosis demand, hospital ICU expansion, outbreak preparedness initiatives, molecular diagnostic adoption, critical care workflow optimization.
The acute care syndromic testing market size is expected to see rapid growth in the next few years. It will grow to $8.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to AI-enabled syndromic panels, expansion of emergency testing, antimicrobial stewardship programs, point-of-care molecular systems, pandemic preparedness focus. Major trends in the forecast period include rapid multiplex pathogen detection, emergency department molecular testing, single-sample multi-disease panels, faster clinical decision support, reduced diagnostic turnaround time.
The increasing prevalence of infectious diseases is expected to drive the growth of the acute care syndromic testing market. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can spread through human contact, animals, or the environment. Factors such as population growth, urbanization, global travel, antimicrobial resistance, and climate change are contributing to the rising incidence of these diseases, increasing the demand for effective diagnostic and treatment solutions. Acute care syndromic testing plays a crucial role in identifying pathogens and co-infections through multiplex molecular diagnostics, allowing for targeted treatment decisions. For example, in February 2024, the UK Health Security Agency reported that in week 4 of 2024, the influenza positivity rate rose to 16.6%, up from 14% the previous week. Influenza-like illness (ILI) consultations also increased, reaching 9.8 per 100,000 people compared to 7.5 per 100,000 in the prior week, while influenza hospitalizations climbed from 5.12 to 7.63 per 100,000. Consequently, the growing incidence of infectious diseases is fueling the expansion of the acute care syndromic testing market.
Leading companies in the acute care syndromic testing market are leveraging advancements in multiplex real-time polymerase chain reaction (PCR) technology to enhance diagnostic accuracy, enable rapid pathogen detection, streamline laboratory workflows, and reduce turnaround time. Multiplex real-time PCR is an advanced molecular diagnostic method that simultaneously detects and quantifies multiple pathogens or genetic targets in a single reaction, improving efficiency and accuracy in disease diagnosis. In April 2023, QIAGEN N.V., a Netherlands-based biotechnology company, launched the QIAstat-Dx syndromic testing solution in Japan. This system features a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from a single sample. Using multiplex real-time PCR technology, it provides rapid results with minimal labor compared to traditional PCR assays. By the end of 2022, over 3,500 QIAstat-Dx systems had been installed worldwide, aiding in the diagnosis of respiratory, gastrointestinal, and meningitis-related conditions. Available in more than 100 countries, this system is improving global access to syndromic testing.
In May 2023, Applied BioCode, a US-based biotechnology company, partnered with Medline Industries to expand the distribution of the BioCode MDx-3000 System. This collaboration aims to enhance access to diagnostic testing for hospitals and reference laboratories across the U.S. Medline Industries LP, a US-based healthcare company specializing in medical supplies and healthcare services, will support the distribution of Applied BioCode’s multiplex diagnostic solutions, further advancing syndromic testing capabilities.
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute care syndromic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have increased costs of reagents, cartridges, and molecular testing platforms in the acute care syndromic testing market. Respiratory and gastrointestinal panels are most affected, particularly in regions reliant on imported diagnostics. However, tariffs have accelerated local manufacturing and innovation in compact, cost-efficient testing systems.
The acute care syndromic testing market research report is one of a series of new reports that provides acute care syndromic testing market statistics, including acute care syndromic testing industry global market size, regional shares, competitors with a acute care syndromic testing market share, detailed acute care syndromic testing market segments, market trends and opportunities, and any further data you may need to thrive in the acute care syndromic testing industry. This acute care syndromic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Acute care syndromic testing is a rapid molecular diagnostic approach that detects multiple pathogens simultaneously from a single patient sample. Primarily used in emergency and critical care settings, it enables quicker diagnosis of infectious diseases, leading to faster treatment decisions, improved patient outcomes, and reduced hospital stays.
The main disease types in the acute care syndromic testing market include respiratory diseases, gastrointestinal diseases, genitourinary diseases, tropical diseases, and others. Respiratory diseases affect the lungs, airways, and respiratory tract, causing symptoms such as coughing, shortness of breath, and fever. Various sample types used for testing include blood, urine, biofluids, stool, swabs, and more. The tests target bacteria, viruses, fungi, and parasites and are utilized in hospitals, clinical and diagnostic laboratories, research and academic institutions, and other healthcare settings.
The acute care syndromic testing market consists of revenues earned by entities by providing services such as comprehensive pathogen detection, rapid turnaround time, and support for antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute care syndromic testing market also includes sales of blood collection tubes, or urine containers, PCR and RT-PCR machines, and reader devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The acute care syndromic testing market size is expected to see rapid growth in the next few years. It will grow to $8.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to AI-enabled syndromic panels, expansion of emergency testing, antimicrobial stewardship programs, point-of-care molecular systems, pandemic preparedness focus. Major trends in the forecast period include rapid multiplex pathogen detection, emergency department molecular testing, single-sample multi-disease panels, faster clinical decision support, reduced diagnostic turnaround time.
The increasing prevalence of infectious diseases is expected to drive the growth of the acute care syndromic testing market. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can spread through human contact, animals, or the environment. Factors such as population growth, urbanization, global travel, antimicrobial resistance, and climate change are contributing to the rising incidence of these diseases, increasing the demand for effective diagnostic and treatment solutions. Acute care syndromic testing plays a crucial role in identifying pathogens and co-infections through multiplex molecular diagnostics, allowing for targeted treatment decisions. For example, in February 2024, the UK Health Security Agency reported that in week 4 of 2024, the influenza positivity rate rose to 16.6%, up from 14% the previous week. Influenza-like illness (ILI) consultations also increased, reaching 9.8 per 100,000 people compared to 7.5 per 100,000 in the prior week, while influenza hospitalizations climbed from 5.12 to 7.63 per 100,000. Consequently, the growing incidence of infectious diseases is fueling the expansion of the acute care syndromic testing market.
Leading companies in the acute care syndromic testing market are leveraging advancements in multiplex real-time polymerase chain reaction (PCR) technology to enhance diagnostic accuracy, enable rapid pathogen detection, streamline laboratory workflows, and reduce turnaround time. Multiplex real-time PCR is an advanced molecular diagnostic method that simultaneously detects and quantifies multiple pathogens or genetic targets in a single reaction, improving efficiency and accuracy in disease diagnosis. In April 2023, QIAGEN N.V., a Netherlands-based biotechnology company, launched the QIAstat-Dx syndromic testing solution in Japan. This system features a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from a single sample. Using multiplex real-time PCR technology, it provides rapid results with minimal labor compared to traditional PCR assays. By the end of 2022, over 3,500 QIAstat-Dx systems had been installed worldwide, aiding in the diagnosis of respiratory, gastrointestinal, and meningitis-related conditions. Available in more than 100 countries, this system is improving global access to syndromic testing.
In May 2023, Applied BioCode, a US-based biotechnology company, partnered with Medline Industries to expand the distribution of the BioCode MDx-3000 System. This collaboration aims to enhance access to diagnostic testing for hospitals and reference laboratories across the U.S. Medline Industries LP, a US-based healthcare company specializing in medical supplies and healthcare services, will support the distribution of Applied BioCode’s multiplex diagnostic solutions, further advancing syndromic testing capabilities.
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute care syndromic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have increased costs of reagents, cartridges, and molecular testing platforms in the acute care syndromic testing market. Respiratory and gastrointestinal panels are most affected, particularly in regions reliant on imported diagnostics. However, tariffs have accelerated local manufacturing and innovation in compact, cost-efficient testing systems.
The acute care syndromic testing market research report is one of a series of new reports that provides acute care syndromic testing market statistics, including acute care syndromic testing industry global market size, regional shares, competitors with a acute care syndromic testing market share, detailed acute care syndromic testing market segments, market trends and opportunities, and any further data you may need to thrive in the acute care syndromic testing industry. This acute care syndromic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Acute care syndromic testing is a rapid molecular diagnostic approach that detects multiple pathogens simultaneously from a single patient sample. Primarily used in emergency and critical care settings, it enables quicker diagnosis of infectious diseases, leading to faster treatment decisions, improved patient outcomes, and reduced hospital stays.
The main disease types in the acute care syndromic testing market include respiratory diseases, gastrointestinal diseases, genitourinary diseases, tropical diseases, and others. Respiratory diseases affect the lungs, airways, and respiratory tract, causing symptoms such as coughing, shortness of breath, and fever. Various sample types used for testing include blood, urine, biofluids, stool, swabs, and more. The tests target bacteria, viruses, fungi, and parasites and are utilized in hospitals, clinical and diagnostic laboratories, research and academic institutions, and other healthcare settings.
The acute care syndromic testing market consists of revenues earned by entities by providing services such as comprehensive pathogen detection, rapid turnaround time, and support for antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute care syndromic testing market also includes sales of blood collection tubes, or urine containers, PCR and RT-PCR machines, and reader devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Acute Care Syndromic Testing Market Characteristics
3. Acute Care Syndromic Testing Market Supply Chain Analysis
4. Global Acute Care Syndromic Testing Market Trends and Strategies
5. Acute Care Syndromic Testing Market Analysis of End Use Industries
7. Global Acute Care Syndromic Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Acute Care Syndromic Testing Total Addressable Market (TAM) Analysis for the Market
9. Acute Care Syndromic Testing Market Segmentation
10. Acute Care Syndromic Testing Market Regional and Country Analysis
11. Asia-Pacific Acute Care Syndromic Testing Market
12. China Acute Care Syndromic Testing Market
13. India Acute Care Syndromic Testing Market
14. Japan Acute Care Syndromic Testing Market
15. Australia Acute Care Syndromic Testing Market
16. Indonesia Acute Care Syndromic Testing Market
17. South Korea Acute Care Syndromic Testing Market
18. Taiwan Acute Care Syndromic Testing Market
19. South East Asia Acute Care Syndromic Testing Market
20. Western Europe Acute Care Syndromic Testing Market
21. UK Acute Care Syndromic Testing Market
22. Germany Acute Care Syndromic Testing Market
23. France Acute Care Syndromic Testing Market
24. Italy Acute Care Syndromic Testing Market
25. Spain Acute Care Syndromic Testing Market
26. Eastern Europe Acute Care Syndromic Testing Market
27. Russia Acute Care Syndromic Testing Market
28. North America Acute Care Syndromic Testing Market
29. USA Acute Care Syndromic Testing Market
30. Canada Acute Care Syndromic Testing Market
31. South America Acute Care Syndromic Testing Market
32. Brazil Acute Care Syndromic Testing Market
33. Middle East Acute Care Syndromic Testing Market
34. Africa Acute Care Syndromic Testing Market
36. Acute Care Syndromic Testing Market Competitive Landscape and Company Profiles
37. Acute Care Syndromic Testing Market Other Major and Innovative Companies
40. Acute Care Syndromic Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Acute Care Syndromic Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses acute care syndromic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for acute care syndromic testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute care syndromic testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Disease Type: Respiratory Diseases; Gastrointestinal Diseases; Genitourinary Diseases; Tropical Diseases; Other Disease Types2) By Sample Type: Blood; Urine; Biofluids; Stool; Swabs; Other Sample Types
3) By Target: Bacteria; Viruses; Fungi; Parasites
4) By End User: Hospitals; Clinical And Diagnostic Laboratories; Research And Academic Institutions; Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza; Respiratory Syncytial Virus (RSV); COVID-19; Tuberculosis; Other Respiratory Diseases2) By Gastrointestinal Diseases: Clostridium Difficile Infection; Norovirus; Rotavirus; Salmonella; Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs); Sexually Transmitted Infections (STIs); Vaginal Infections; Other Genitourinary Diseases
4) By Tropical Diseases: Malaria; Dengue; Chikungunya; Zika Virus; Other Tropical Diseases
5) By Other Disease Types: Meningitis; Sepsis; Other Emerging Infectious Diseases
Companies Mentioned: Siemens Healthineers AG; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Danaher Corporation; Becton Dickinson and Company; Seegene Inc.; bioMérieux SA; Sysmex Corporation; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Werfen; DiaSorin S.p.A.; Quidel Corporation; Luminex Corporation; Biocartis NV; Microbiologics Inc.; QuantuMDx Group Ltd.; Curetis GmbH by OpGen Inc.; Genetic Signatures Ltd.; Applied BioCode Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Acute Care Syndromic Testing market report include:- Siemens Healthineers AG
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Becton Dickinson and Company
- Seegene Inc.
- bioMérieux SA
- Sysmex Corporation
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Werfen
- DiaSorin S.p.A.
- Quidel Corporation
- Luminex Corporation
- Biocartis NV
- Microbiologics Inc.
- QuantuMDx Group Ltd.
- Curetis GmbH by OpGen Inc.
- Genetic Signatures Ltd.
- Applied BioCode Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.17 Billion |
| Forecasted Market Value ( USD | $ 8.3 Billion |
| Compound Annual Growth Rate | 12.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
